These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3279968)

  • 1. Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia.
    Taskinen MR; Nikkilä EA
    Atherosclerosis; 1988 Feb; 69(2-3):249-55. PubMed ID: 3279968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathologic decrease in lipoprotein lipase activity in relation to the development of hyperlipemias and their significance for coronary heart disease].
    Breier C
    Wien Klin Wochenschr Suppl; 1986; 167():1-16. PubMed ID: 3458343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes of high density lipoprotein subfraction concentration and composition by intralipid in vivo and by lipolysis of intralipid in vitro.
    Taskinen MR; Nikkilä EA; Kuusi T; Tulikoura I
    Arteriosclerosis; 1983; 3(6):607-15. PubMed ID: 6651616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
    Series JJ; Gaw A; Kilday C; Bedford DK; Lorimer AR; Packard CJ; Shepherd J
    Br J Clin Pharmacol; 1990 Jul; 30(1):49-54. PubMed ID: 2390432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.
    Simons LA; Hickie JB; Balasubramaniam S
    Atherosclerosis; 1985 Jan; 54(1):75-88. PubMed ID: 3888229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.
    Crepaldi G; Avogaro P; Descovich GC; Di Perri T; Postiglione A; Sirtori CR; Strano A; Ventura S; Musatti L
    Atherosclerosis; 1988 Mar; 70(1-2):115-21. PubMed ID: 3281679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.
    Otto C; Parhofer KG; Ritter MM; Richter WO; Schwandt P
    Br J Clin Pharmacol; 1998 Nov; 46(5):473-8. PubMed ID: 9833601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-density lipoprotein cholesterol concentrations and postheparin hepatic and lipoprotein lipases in obesity: relationships with plasma insulin levels.
    Cominacini L; Garbin U; Davoli A; Campagnola M; De Santis A; Pasini C; Pastorino AM; Bosello O
    Ann Nutr Metab; 1993; 37(4):175-84. PubMed ID: 8215234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity.
    Kahri J; Vuorinen-Markkola H; Tilly-Kiesi M; Lahdenperä S; Taskinen MR
    Atherosclerosis; 1993 Aug; 102(1):79-89. PubMed ID: 8257455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preheparin and postheparin lipids of high density lipoprotein subfractions: relation to the serum insulin and postheparin plasma lipase activities in normal human.
    Skottová N; Vaverková H; Vecera R; Bartek J
    Acta Univ Palacki Olomuc Fac Med; 1992; 134():69-74. PubMed ID: 1364970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control.
    Shih KC; Kwok CF; Hwu CM; Hsiao LC; Li SH; Liu YF; Ho LT
    Diabetes Res Clin Pract; 1997 May; 36(2):113-9. PubMed ID: 9229195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients.
    Kahri J; Sane T; van Tol A; Taskinen MR
    J Intern Med; 1995 Nov; 238(5):429-36. PubMed ID: 7595182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women.
    Després JP; Ferland M; Moorjani S; Nadeau A; Tremblay A; Lupien PJ; Thériault G; Bouchard C
    Arteriosclerosis; 1989; 9(4):485-92. PubMed ID: 2751477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxandrolone and plasma triglyceride reduction: effect on triglyceride-rich and high density lipoproteins.
    Hara T; Miller JP; Gotto AM; Patsch JR
    Artery; 1981; 9(5):328-41. PubMed ID: 7316782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability.
    Tornvall P; Walldius G
    J Intern Med; 1991 Nov; 230(5):415-21. PubMed ID: 1940776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
    Koev D; Zlateva S; Susic M; Babic D; Profozic V; Skrabalo Z; Langrová H; Cvrkalová AL; Rajecová E; Klimes I
    Diabetes Care; 1993 Sep; 16(9):1285-90. PubMed ID: 8404433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.